	US 12,139,534 B2
	Methods and compositions for decreasing soluble immune receptor CD28
Motti Hakim, Kibbutz Gazit (IL); Dror Alishekevitz, Kiryat Tivon (IL); Dana Haves Ziv, Karmiel (IL); Edna Meilin, Kfar Veradim (IL); Yair Sapir, Manof (IL); Avidor Shulman, Rakefet (IL); Tehila Ben-Moshe, Tel Aviv (IL); and Ilana Mandel, Manof (IL)
Assigned to BIOND BIOLOGICS LTD., Misgav (IL)
Appl. No. 16/980,409
Filed by BIOND BIOLOGICS LTD., Misgav (IL)
PCT Filed Mar. 14, 2019, PCT No. PCT/IL2019/050292 § 371(c)(1), (2) Date Sep. 13, 2020, PCT Pub. No. WO2019/175885, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/643,334, filed on Mar. 15, 2018.
Claims priority of provisional application 62/643,355, filed on Mar. 15, 2018.
Claims priority of provisional application 62/774,254, filed on Dec. 2, 2018.
Prior Publication US 2021/0047411 A1, Feb. 18, 2021
Int. Cl. A61K 45/06 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/2818 (2013.01) [C07K 16/2827 (2013.01); G01N 33/57488 (2013.01); A61K 45/06 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); G01N 2333/70521 (2013.01); G01N 2500/04 (2013.01)]

10 Claims

1. A method of improving PD-1/PD-L1 based immunotherapy in a subject suffering from cancer, the method comprising decreasing soluble CD28 (sCD28) levels in said subject; thereby improving PD-1/PD-L1 based immunotherapy.